Physician profile
Randolph Ramirez
NPI 1629178843
$4,675.43
in general payments reported to CMS, 2019-2025
29 companies · $512 in 2025
The $512 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $375 · 2021: $1,088 · 2022: $1,333 · 2023: $628 · 2024: $358 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,497.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,197.54 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $1,073.47 | 2021-2025 | |
| Glaxosmithkline, LLC. | $377.23 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $252.35 | 2020-2024 | Trintellix |
| Lilly USA, LLC | $241.30 | 2019-2025 | Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $225.68 | 2020-2024 | Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $224.02 | 2019-2025 | Capvaxive, Gardasil 9 |
| Amgen INC. | $198.88 | 2021-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $165.97 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.74 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.72 | 2022-2023 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $75.96 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $54.61 | 2022 | |
| Ironwood Pharmaceuticals, INC | $34.25 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.37 | 2025 | Caplyta |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $28.46 | 2020-2023 | |
| Vistapharm, INC. | $26.33 | 2021 | |
| Exact Sciences Corporation | $25.83 | 2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $21.78 | 2023 | |
| Gilead Sciences, INC. | $21.31 | 2019 | |
| Idorsia Pharmaceuticals US INC | $20.83 | 2022 | |
| Inspire Medical Systems, INC. | $20.73 | 2024 | Inspire |
| Teva Pharmaceuticals USA, INC. | $19.67 | 2025 | Austedo Xr |
| Medtronic, INC. | $19.65 | 2025 | Closurefast |
| Philips North America LLC | $15.95 | 2023 | |
| Janssen Pharmaceuticals, INC | $15.21 | 2023 | Invega Sustenna |
| Seqirus USA INC | $14.78 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Collegium Pharmaceutical, INC. | $13.50 | 2022 | |
| Redhill Biopharma INC. | $13.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randolph Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.